Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil

Published on 7 May 2024 on Zacks via Yahoo Finance

Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil

Rocket Pharmaceutical RCKT reported a loss of 66 cents per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, the company posted a loss of 73 cents.

As the company lacks any marketed product in its portfolio, it did not record any revenues during the quarter.

Quarter in Detail

Read the rest of the article

NASDAQ.RCKT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article,...

Insider Monkey · via Yahoo Finance 29 Dec 2024

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, w...

Insider Monkey · via Yahoo Finance 21 Nov 2024

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future...

On Monday, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) presented long-term safety and efficacy...

Benzinga · via Yahoo Finance 19 Nov 2024

Children’s Hospital of Philadelphia Researchers | Newswise

Researchers at Children’s Hospital of Philadelphia (CHOP) announced encouraging results from the...

Newswise 18 Nov 2024

FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks...

FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, St...

Benzinga · via Yahoo Finance 20 Jun 2024

Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil

Rocket Pharmaceutical RCKT reported a loss of 66 cents per share in the first quarter of 2024, na...

Zacks via Yahoo Finance 7 May 2024

Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarte...

Insider Monkey via Yahoo Finance 24 Apr 2024

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

Rocket Pharmaceuticals RCKT announced that the EMA accepted the marketing authorization applicati...

Zacks via Yahoo Finance 3 Apr 2024

Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quart...

Insider Monkey via Yahoo Finance 22 Jan 2024

Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at Ro...

Simply Wall St. via Yahoo Finance 15 Jan 2024